

Express Mail No. ER 930264028 US  
Docket No. K21372USWO (C038435/0184372)

10/525348  
DT01 Rec'd PCT/FT 22 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS  
DESIGNATED/ELECTED OFFICE (DO/EO/US) UNDER THE PATENT  
COOPERATION TREATY CONCERNING A FILING UNDER 35 U.S.C. §371

*In re* International Application of: )  
Manfred Ludwig EGGERSDORFER *et al.* )  
Based on Int'l Application No.: PCT/EP2003/009112 ) Examiner: Not yet assigned  
International Filing Date: 18 August 2003 ) Art Unit: Not yet assigned  
Filed: Herewith )  
For: **NOVEL NUTRACEUTICAL COMPOSITIONS** )  
**COMPRISING BIOTIN** )

New York, NY  
February 22, 2005

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants wish to make of record the following documents (clean copies and a Form PTO-1449 listing the documents are enclosed). The following documents were cited in the International Search Report, mailed December 12, 2003, in the International application corresponding to the above-captioned case.

**US PATENT DOCUMENTS**

	<b><u>Document No.</u></b>	<b><u>Date</u></b>
A1	6,203,819	3/20/2001

**Document No.**

10/525348  
PTO Rec'd PCT/PT  
Date 22 FEB 2005

A2	6,103,756	8/15/2000
A3	5,976,568	11/2/1999
A4	6,291,533	9/18/2001
A5	5,922,704	7/13/1999

**FOREIGN PATENT DOCUMENTS**

	<b><u>Document No.</u></b>	<b><u>Date</u></b>	<b><u>Country</u></b>
B1	WO 03/028747 A1	4/10/1993	PCT
B2	WO 02/076436 A2	10/3/2002	PCT
B3	WO 02/47493 A2	6/20/2002	PCT
B4	EP 1 177 789 A2	2/6/2002	Europe

**OTHER PUBLICATIONS**

- C1    McCarty, M.F., "*Toward Practical Prevention of Type 2 Diabetes,*" Medical Hypotheses, Vol. 54, no. 5, pp. 786-793 (2000).
- C2    McCarty, M.F., "*High-Dose Biotin, an Inducer of Glucokinase Expression, May Synergize with Chromium Picolinate to Enable a Definitive Nutritional Therapy for Type II Diabetes,*" Biosis Database Abstract No. XP-002262310 (1999).

The Examiner's independent consideration of all of these documents and their relevance before issuance of the first official action is respectfully requested. The Examiner is also requested to initial and return a copy of the accompanying form PTO-1449 to evidence such consideration.

Copies of the International Search Report and International Preliminary Examination Report are included herewith. All documents cited in these reports are identified herein and copies of all documents other than the U.S. Patent Documents are provided. See MPEP § 609(III)(A)(2)(A) (8<sup>th</sup> Ed., Rev. 2, May 2004, p. 600-128); See

also 1276 OG 55 (August 5, 2003) (Waiving the requirement under Rule 98(a)(2)(1) to provide a copy of each cited U.S. patent document for any application filed after June 30, 2003.).

This Information Disclosure Statement is being filed in accordance with the provisions under 37 C.F.R. §1.97(b)(2), within three months of the date of entry of the national stage of the international application. Accordingly, no fee is believed to be due. If, however, a fee is due, please charge the same to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

If the Examiner has any questions regarding this paper, please contact the undersigned attorney.

Respectfully submitted,

By: 

Stephen J. Brown  
 Registration No. 43,519  
 BRYAN CAVE LLP  
 1290 Avenue of the Americas  
 New York, NY 10104  
 Phone: (212) 541-2000  
 Fax: (212) 541-4630

also 1276 OG 55 (August 5, 2003) (Waiving the requirement under Rule 98(a)(2)(1) to provide a copy of each cited U.S. patent document for any application filed after June 30, 2003.).

This Information Disclosure Statement is being filed in accordance with the provisions under 37 C.F.R. §1.97(b)(2), within three months of the date of entry of the national stage of the international application. Accordingly, no fee is believed to be due. If, however, a fee is due, please charge the same to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

If the Examiner has any questions regarding this paper, please contact the undersigned attorney.

Respectfully submitted,

By: 

Stephen J. Brown  
Registration No. 43,519  
BRYAN CAVE LLP  
1290 Avenue of the Americas  
New York, NY 10104  
Phone: (212) 541-2000  
Fax: (212) 541-4630

Form PTO-1449 (Rev. )  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.  K21372USWO (C038435/0184372)	INTERNATIONAL APPLICATION NO.: 10/525348 PCT/EP2003/009112
	APPLICANT Manfred Ludwig EGGERSDORFER <i>et al.</i>		
	INTERNATIONAL FILING DATE 18 August 2003	GROUP Not Yet Assigned	

## U.S. PATENT DOCUMENTS

Examiner Initial	CiteNo.	U.S. Patent Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	6,203,819	3/20/2001	Fine			
	A2	6,103,756	8/15/2000	Gorsek			
	A3	5,976,568	11/2/1999	Riley			
	A4	6,291,533	9/18/2001	Fleischner			
	A5	5,922,704	7/13/1999	Bland			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 03/028747 A1	4/10/1993	PCT				
	B2	WO 02/076436 A2	10/3/2002	PCT				
	B3	WO 02/47493 A2	6/20/2002	PCT				
	B4	EP 1 177 789 A2	2/6/2002	Europe				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	McCarty, M.F., "Toward Practical Prevention of Type 2 Diabetes," <u>Medical Hypotheses</u> , Vol. 54, no. 5, pp. 786-793 (2000).
C2	McCarty, M.F., "High-Dose Biotin, an Inducer of Glucokinase Expression, May Synergize with Chromium Picolinate to Enable a Definitive Nutritional Therapy for Type II Diabetes," <u>Biosis Database Abstract No. XP-002262310</u> (1999).
EXAMINER  Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
DATE CONSIDERED	